Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non-Small-Cell Lung Cancer
about
Towards tumor immunodiagnosticsNew targeted treatments for non-small-cell lung cancer - role of nivolumabHeterogeneity of CD8+ tumor-infiltrating lymphocytes in non-small-cell lung cancer: impact on patient prognostic assessments and comparison of quantification by different sampling strategiesAn Analytical Comparison of Dako 28-8 PharmDx Assay and an E1L3N Laboratory-Developed Test in the Immunohistochemical Detection of Programmed Death-Ligand 1.Current state of immunotherapy for non-small cell lung cancer.Clinical applications of PD-L1 bioassays for cancer immunotherapy.Anti-PD-1 increases the clonality and activity of tumor infiltrating antigen specific T cells induced by a potent immune therapy consisting of vaccine and metronomic cyclophosphamide.Variability in Immunohistochemical Detection of Programmed Death Ligand 1 (PD-L1) in Cancer Tissue Types.Expression of PD-L1 in triple-negative breast cancer based on different immunohistochemical antibodies.Predictive Biomarkers for PD-1 Axis Therapies: The Hidden Treasure or a Call for Research.Programmed cell death ligand-1 (PD-L1) expression by immunohistochemistry: could it be predictive and/or prognostic in non-small cell lung cancer?Immunoscore and Immunoprofiling in cancer: an update from the melanoma and immunotherapy bridge 2015Temporal and spatial discordance of programmed cell death-ligand 1 expression and lymphocyte tumor infiltration between paired primary lesions and brain metastases in lung cancer.Clinical significance of PD-L1 and PD-L2 copy number gains in non-small-cell lung cancer.Abundant PD-L1 expression in Epstein-Barr Virus-infected gastric cancersMetastatic lymphoepithelioma-like carcinoma of the lung treated with nivolumab: a case report and focused review of literaturePrognostic value of PDL1 expression in pancreatic cancerPD-L1 Expression in Lung Cancer.Immunological profiling of molecularly classified high-risk endometrial cancers identifies POLE-mutant and microsatellite unstable carcinomas as candidates for checkpoint inhibition.Nuclear IRF-1 expression as a mechanism to assess "Capability" to express PD-L1 and response to PD-1 therapy in metastatic melanoma.Update on Programmed Death-1 and Programmed Death-Ligand 1 Inhibition in the Treatment of Advanced or Metastatic Non-Small Cell Lung Cancer.The Era of Checkpoint Blockade in Lung Cancer: Taking the Brakes Off the Immune System.Immunotherapy in Breast Cancer: the Emerging Role of PD-1 and PD-L1.PDL-1/PD1 inhibitors: antibody or antinobody?Emerging role of nivolumab in the management of patients with non-small-cell lung cancer: current data and future perspectives.AKT1low quiescent cancer cells persist after neoadjuvant chemotherapy in triple negative breast cancer.Monitoring immune-checkpoint blockade: response evaluation and biomarker development.Cell genomics and immunosuppressive biomarker expression influence PD-L1 immunotherapy treatment responses in HNSCC-a computational study.Predicting PD-L1 expression on human cancer cells using next-generation sequencing information in computational simulation models.Assessment of the PD-L1 status by immunohistochemistry: challenges and perspectives for therapeutic strategies in lung cancer patients.PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer.Quantitative and pathologist-read comparison of the heterogeneity of programmed death-ligand 1 (PD-L1) expression in non-small cell lung cancer.EGFR-GRB2 Protein Colocalization Is a Prognostic Factor Unrelated to Overall EGFR Expression or EGFR Mutation in Lung AdenocarcinomaTargeting PD-L1 for non-small-cell lung cancer.PD-L1 (CD274) copy number gain, expression, and immune cell infiltration as candidate predictors for response to immune checkpoint inhibitors in soft-tissue sarcoma.Checkpoint Inhibitors in Head and Neck Cancer: Rationale, Clinical Activity, and Potential Biomarkers.The pathway to clinical use of a cancer biomarker.Advances in the Treatment of Non-small Cell Lung Cancer: Focus on Nivolumab, Pembrolizumab, and Atezolizumab.Analysis of the prognostic role of an immune checkpoint score in resected non-small cell lung cancer patients.Making urothelial carcinomas less immune to immunotherapy.
P2860
Q26738691-7F8542C5-A6AC-42E8-B622-45A9981930A4Q26740988-1792D1C2-161A-4AB1-9560-97DEEEA914CDQ30275647-5AD7A2B4-C0F7-4E74-ACDA-C30181B58A1CQ30489890-5BFD69D6-7271-4579-859F-BE59CD1CE5D6Q33645595-B9521710-DEFE-4FEA-BA8D-023D424822F7Q33702815-69C3CC0E-2281-46D3-BBE7-AC3F6AB3983FQ36173622-47A63257-8715-4C48-A02E-FA4C8ED7853DQ36939402-6739AFDC-4B4F-40C6-AE93-C4D9C92BEAA8Q36994508-D0E4A9CB-B0CE-4F21-9A6A-BE96656E38D9Q37083326-2313A7A4-36BA-488F-AFE6-97CAA879977CQ37094056-7D72F176-CA53-440A-AC1A-29D0F4293ED1Q37267893-AF2FF415-8171-4863-9DCF-7C7D180B0198Q37281262-31FDD22F-254C-4A4D-B465-BB7749B99B34Q37362623-B1474992-27EC-41FE-BAAE-CB6C935A3866Q37362803-F0B95C7C-117F-456C-8350-E188B9D888B9Q37584406-A140002C-F713-430A-B3E2-2B0713226C29Q37687595-7E9F3E3F-E4B5-471F-B01D-8CA16A699A23Q37704352-5E1BCE51-32B5-47A2-BABB-AC1410C34018Q37705031-0A864524-F2C2-47E6-8DE4-2B40BCC23883Q37713503-C97603C9-0E04-49F2-86F9-583E39445D23Q37739214-132AACE2-6995-4CC0-BAFF-6FC6563668BDQ38401891-8180DCC4-9B54-4F07-B598-FF85D6F67CAFQ38629357-3196D678-6330-4004-8BE4-9A67E0E7F4A6Q38638443-2D6D033B-42AF-46FE-A8B0-12A6CF72EDACQ38645803-792BAD52-5851-4E52-9711-1FFE4ED2C203Q38648335-031929BF-C5D6-4038-9946-EC95DBEC8EB8Q38666241-FA74ACE6-D02A-4E5F-A7BE-D99DE25CA689Q38696133-5D9B0CE4-4AAD-4178-ABDC-D59075E35CD7Q38743088-D998DAA1-9A74-40F1-8C59-FCE2C758A0DFQ38749966-11F9A1A5-D10F-4409-B6BE-2F1C85ED7530Q38754407-4F64ACCB-5D1E-439E-9CBE-AB95121C7280Q38796541-633170E3-A196-413D-AADE-E66CD1DCBBD3Q38807586-15EE1C9E-FAEC-483C-A60D-22C8369F9C59Q38838651-1B014DC1-FC54-4C4B-8059-C3016C72EF00Q38839136-9EB62259-9494-4FFB-AD58-59D1E65F4EC2Q38868396-C67499CE-2043-4FB0-BCE2-BAB516307CC2Q38895171-89D919D8-0D53-49CF-9DC4-01380833D5F2Q38895586-96B93B60-5585-4499-9158-44F9E19620C0Q38961444-0999E1AA-84BA-4159-A653-3D4726DCA165Q39005601-8CD74D05-DB97-4B39-AC72-8C4781260F81
P2860
Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non-Small-Cell Lung Cancer
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Quantitative Assessment of the ...... in Non-Small-Cell Lung Cancer
@en
Quantitative Assessment of the ...... in Non-Small-Cell Lung Cancer.
@nl
type
label
Quantitative Assessment of the ...... in Non-Small-Cell Lung Cancer
@en
Quantitative Assessment of the ...... in Non-Small-Cell Lung Cancer.
@nl
prefLabel
Quantitative Assessment of the ...... in Non-Small-Cell Lung Cancer
@en
Quantitative Assessment of the ...... in Non-Small-Cell Lung Cancer.
@nl
P2093
P2860
P50
P1433
P1476
Quantitative Assessment of the ...... in Non-Small-Cell Lung Cancer
@en
P2093
Daniel Carvajal-Hausdorf
David L Rimm
Jamaal Rehman
Joseph McLaughlin
Patricia LoRusso
Vamsidhar Velcheti
P2860
P356
10.1001/JAMAONCOL.2015.3638
P577
2016-01-01T00:00:00Z